-
<![CDATA[Imdelltra Improves Survival For Some With Small Cell Lung Cancer]]>
19 Oct 2025 00:00 GMT
Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab … line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free … tarlatamab-dlle for extensive stage small cell lung cancer,” news release. https:…
-
<![CDATA[Addressing Drug Resistance in Lung Cancer ]]>
19 Oct 2025 02:24 GMT
… example, EGFR-mutant lung cancers can develop compound mutations … is transformation into small cell lung cancer (SCLC). These transformed tumors … option in resistant lung cancers, including those with … patient outcomes in resistant lung cancers,” Jänne said.
…
-
<![CDATA[From Mutation to Medicine: Targeted Therapies in Lung Cancer]]>
18 Oct 2025 21:25 GMT
… 1% to 4% of lung cancers, most often in … Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA). … growth factor receptor non-small cell lung cancer (FLAURA2) (FLAURA2). … or metastatic non-small cell lung cancer (MARIPOSA). Clinicaltrials.gov …
-
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
18 Oct 2025 10:05 GMT
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains … CEACAM5, and to classify SCLC molecular subtypes. These findings … longitudinal disease monitoring in SCLC.” Data presented at … Target Expression in SCLC About Precede Biosciences
…
-
Chemotherapy Combination Boosts Overall Survival in Patients with EGFR-mutant Non-Small Cell Lung Cancer
18 Oct 2025 02:57 GMT
… diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone … newly diagnosed EGFR-mutant non-small cell lung cancer, including combination therapies and monotherapies …
-
<![CDATA[Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups]]>
18 Oct 2025 22:01 GMT
… chemotherapy among patients with small cell lung cancer (SCLC) regardless of chemotherapy-free … line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free … -dlle for extensive stage small cell lung cancer. News release. FDA. …
-
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and…
17 Oct 2025 14:49 GMT
AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC
AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities
Promising efficacies were observed in patients with …
-
<![CDATA[Imdelltra Plus Chemoimmunotherapy Safely Elicits Responses in ES-SCLC]]>
18 Oct 2025 19:01 GMT
… with extensive-stage (ES) small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab) … for patients with ES-SCLC comprises chemoimmunotherapy followed by … chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study,” …
-
<![CDATA[Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC]]>
18 Oct 2025 17:13 GMT
… with extensive-stage (ES) small cell lung cancer (SCLC), according to cohort results … chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. … First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (DeLLphi-312). …
-
New therapy may extend life for lung cancer patients
18 Oct 2025 03:24 GMT
Lung cancer is the leading cause … battling a certain type of lung cancer, there’s good news. … targeted therapy is significantly improving lung cancer patient outcomes. The drug is … patients with Stage Three Non-Small Cell Lung Cancer. These patients also had a …
About
© 1995-2025